Open AccessOlanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study
Author(s) -
G Shivaprakash,
Karthik S Udupa,
V Sarayu,
T Joseph,
Vishal Gupta,
LC Pallavi,
Sudhakar Pemminati
Publication year - 2017
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/ijp.ijp_846_16
Subject(s) - aprepitant , nausea , medicine , vomiting , breast cancer , cyclophosphamide , antiemetic , regimen , olanzapine , chemotherapy induced nausea and vomiting , anthracycline , chemotherapy , mucositis , anesthesia , cancer , gastroenterology , schizophrenia (object oriented programming) , psychiatry
Despite the guideline-directed therapy, complete absence of nausea was noted only in 33% of breast cancer patients on anthracycline-cyclophosphamide regimen. Hence, we sought to compare the efficacy of aprepitant (APT) versus olanzapine (OLP) in preventing chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients on doxorubicin-cyclophosphamide regimen.